PDF(Pubmed)
Abstract：
UNASSIGNED: The study investigated Ethion-induced developmental toxicity in Wistar albino rats and the potential ameliorative effects of quercetin and nano-quercetin co-administration. Further, In-silico docking of Ethion and quercetin with MCL-1 was conducted.
UNASSIGNED: Quercetin nanoparticles were synthesized by ionic-gelation method. The encapsulated quercetin nanoparticles were characterized for Zeta size, UV-Vis spectroscopy, encapsulation efficiency, and TEM studies. Male rats were administered Ethion (high/low dose), quercetin, and nano-quercetin alone or in combination for 60 days. Female rats were introduced for mating on the 61st day, and pregnant females were observed for 20 gestational days. On GD 20, rats were sacrificed and evaluated for body/organ weight, reproductive indices, fetal morphology, skeletal, and visceral deformities.In silico binding energies of ethion and quercetin with MCL-1 were determined.
UNASSIGNED: Nanoparticle size was 363.2 ± 1.23 nm on day 0 and 385.63 ± 1.53 nm on day 60, with PDI of 0.247 and charge of 22.9 mV. Absorbance maxima were at 374 nm, with encapsulation efficacy of 85.16 ± 0.33%. EHD male crossed females showed decreased body/organ weights, reduced fertility, hematoma, cleft palate, tail curling, and absence of extremity. Nano-quercetin co-administration normalized parameters comparable to controls. Both Ethion and quercetin interacted with MCL-1, with quercetin exhibiting stronger binding energy.
UNASSIGNED: Nano-quercetin demonstrated stronger antioxidant properties than quercetin, counteracting ethion-induced maternal/fetal abnormalities.
UNASSIGNED: Quercetin nanoparticles were synthesized by ionic-gelation method. The encapsulated quercetin nanoparticles were characterized for Zeta size, UV-Vis spectroscopy, encapsulation efficiency, and TEM studies. Male rats were administered Ethion (high/low dose), quercetin, and nano-quercetin alone or in combination for 60 days. Female rats were introduced for mating on the 61st day, and pregnant females were observed for 20 gestational days. On GD 20, rats were sacrificed and evaluated for body/organ weight, reproductive indices, fetal morphology, skeletal, and visceral deformities.In silico binding energies of ethion and quercetin with MCL-1 were determined.
UNASSIGNED: Nanoparticle size was 363.2 ± 1.23 nm on day 0 and 385.63 ± 1.53 nm on day 60, with PDI of 0.247 and charge of 22.9 mV. Absorbance maxima were at 374 nm, with encapsulation efficacy of 85.16 ± 0.33%. EHD male crossed females showed decreased body/organ weights, reduced fertility, hematoma, cleft palate, tail curling, and absence of extremity. Nano-quercetin co-administration normalized parameters comparable to controls. Both Ethion and quercetin interacted with MCL-1, with quercetin exhibiting stronger binding energy.
UNASSIGNED: Nano-quercetin demonstrated stronger antioxidant properties than quercetin, counteracting ethion-induced maternal/fetal abnormalities.
摘要：
■该研究调查了在Wistar白化病大鼠中Ethion诱导的发育毒性以及槲皮素和纳米槲皮素共同给药的潜在改善作用。Further,进行了Ethion和槲皮素与MCL-1的硅对接。
■通过离子凝胶法合成槲皮素纳米颗粒。表征包封的槲皮素纳米颗粒的Zeta大小，紫外-可见光谱,封装效率，和TEM研究。给雄性大鼠服用Ethion（高/低剂量），槲皮素,和纳米槲皮素单独或联合使用60天。在第61天引入雌性大鼠进行交配，观察孕妇妊娠20天。在GD20时，处死大鼠并评估身体/器官重量，生殖指数，胎儿形态学,骨骼，内脏畸形.测定了乙硫离子和槲皮素与MCL-1的硅结合能。
纳米颗粒尺寸在第0天为363.2±1.23nm,在第60天为385.63±1.53nm,PDI为0.247,电荷为22.9mV。最大吸光度为374nm,包封率为85.16±0.33%。EHD男性交叉女性显示身体/器官重量减少，生育率降低,血肿,腭裂,尾巴卷曲，没有四肢。纳米槲皮素共同给药标准化参数与对照相当。Ethion和槲皮素均与MCL-1相互作用，槲皮素表现出更强的结合能。
■纳米槲皮素表现出比槲皮素更强的抗氧化性能，抵消乙硫磷诱导的母体/胎儿异常。
■通过离子凝胶法合成槲皮素纳米颗粒。表征包封的槲皮素纳米颗粒的Zeta大小，紫外-可见光谱,封装效率，和TEM研究。给雄性大鼠服用Ethion（高/低剂量），槲皮素,和纳米槲皮素单独或联合使用60天。在第61天引入雌性大鼠进行交配，观察孕妇妊娠20天。在GD20时，处死大鼠并评估身体/器官重量，生殖指数，胎儿形态学,骨骼，内脏畸形.测定了乙硫离子和槲皮素与MCL-1的硅结合能。
纳米颗粒尺寸在第0天为363.2±1.23nm,在第60天为385.63±1.53nm,PDI为0.247,电荷为22.9mV。最大吸光度为374nm,包封率为85.16±0.33%。EHD男性交叉女性显示身体/器官重量减少，生育率降低,血肿,腭裂,尾巴卷曲，没有四肢。纳米槲皮素共同给药标准化参数与对照相当。Ethion和槲皮素均与MCL-1相互作用，槲皮素表现出更强的结合能。
■纳米槲皮素表现出比槲皮素更强的抗氧化性能，抵消乙硫磷诱导的母体/胎儿异常。
